Holen Sie sich die Stockscreener-App
464.71
1.92%
-9.08
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt MDGL?
Forum
Prognose
Aktiensplit
Madrigal Pharmaceuticals Inc Aktie (MDGL) Neueste Nachrichten
Why Madrigal Pharmaceuticals Inc. stock is seen as undervaluedWeekly Investment Report & Scalable Portfolio Growth Methods - mfd.ru
Madrigal Pharmaceuticals is Now Oversold (MDGL) - Nasdaq
What are Madrigal Pharmaceuticals Inc.’s recent SEC filings showingMarket Risk Summary & Daily Stock Trend Reports - mfd.ru
MDGL Strengthens MASH Franchise With New Genetic Approaches - Finviz
Madrigal (MDGL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance
Madrigal inks licensing deal with China’s Suzhou Ribo for MASH drugs - MSN
Madrigal expands its MASH pipeline via Ribo deal - The Pharma Letter
Madrigal Pharmaceuticals (MDGL) to Release Earnings on Thursday - MarketBeat
Madrigal Pharmaceuticals Expands Team With Equity Awards to New Hires - MSN
Madrigal expands MASH pipeline with siRNA therapies in $4.4 B deal - BioSpectrum Asia
Suzhou Ribo Life Science Signs Global siRNA Licensing Deal With Madrigal Pharma; Shares Rise 7% - marketscreener.com
What are analysts’ price targets for Madrigal Pharmaceuticals Inc.Price Action & Low Risk Growth Stock Ideas - mfd.ru
Is Madrigal Pharmaceuticals Inc. in a long term uptrendJuly 2025 Retail & Trade Opportunity Analysis Reports - mfd.ru
Madrigal Continues Building Out MASH Pipeline With Ribo Life Science Deal - Citeline News & Insights
What is Madrigal Pharmaceuticals Inc. s revenue forecastJuly 2025 Update & Accurate Trade Setup Notifications - mfd.ru
Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH - Finviz
Madrigal builds in MASH with $4.4bn+ Ribo alliance - pharmaphorum
Madrigal Pharmaceuticals (MDGL) Secures $4.46B Licensing Deal wi - GuruFocus
Madrigal licenses six Ribo siRNA programs - bioworld.com
Madrigal inks licensing deal for MASH drugs (MDGL:NASDAQ) - Seeking Alpha
Madrigal expands its MASH pipeline with exclusive global licensing agreement for six preclinical siRNA programs - marketscreener.com
Madrigal, China's Suzhou Ribo sign license deal for liver-disease programs - marketscreener.com
Madrigal turns to RNAi drugs from China to bolster MASH pipeline - Yahoo Finance
Madrigal, Suzhou Ribo in license deal for liver-disease programs - marketscreener.com
Madrigal Doubles Down On MASH With A $4.4 Billion Licensing Deal With China’s Ribo - Stocktwits
Madrigal Pharmaceuticals (MDGL) Secures Global License for siRNA Programs - GuruFocus
Madrigal Pharmaceuticals, Inc. announced an exclusive global licensing agreement to introduce six preclinical-stage siRNA (small interfering RNA) programs, aiming to significantly expand its research and development pipeline for metabolic dysfunction-asso - Bitget
Madrigal Pharmaceuticals Expands MASH Pipeline with Exclusive License for siRNA Programs - Quiver Quantitative
Madrigal Expands its MASH Pipeline with Exclusive Global Licensing Agreement for Six Preclinical siRNA Programs - GlobeNewswire
Madrigal Pharmaceuticals, Inc. $MDGL Shares Sold by First National Trust Co - MarketBeat
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Ribo Life Science Enters Exclusive Licensing Agreement with Madrigal Pharmaceuticals - Intellectia AI
Madrigal Grants Equity to New Hires as MASH Drug Momentum Builds - MyChesCo
Madrigal Sets Date to Reveal 2025 Results as Investors Watch Closely - MyChesCo
Aug Update: Is Madrigal Pharmaceuticals Inc stock good for income investorsRate Hike & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Madrigal Equity Grants Signal Hiring Push And Undervalued Share Opportunity - Sahm
Madrigal Pharmaceuticals announces grants of inducement awards under Nasdaq Listing Rule - marketscreener.com
Madrigal Pharmaceuticals Announces Grants Of Inducement Awards Under Nasdaq Listing Rule - TradingView
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Commit To Buy Madrigal Pharmaceuticals At $350, Earn 14.6% Annualized Using Options - Nasdaq
Federated Hermes Inc. Takes Position in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Does Madrigal Pharmaceuticals (MDGL) Offer Value After Recent Share Price Weakness - simplywall.st
Madrigal Pharmaceuticals stock maintains Buy rating at B.Riley on strong Rezdiffra growth - Investing.com Canada
Madrigal Pharmaceuticals to report financial results on February 19 - Traders Union
18,291 Shares in Madrigal Pharmaceuticals, Inc. $MDGL Bought by WCM Investment Management LLC - MarketBeat
How (MDGL) Movements Inform Risk Allocation Models - Stock Traders Daily
Novo Set To Make MASH Move On Madrigal In EU With Kayshild - Citeline News & Insights
Madrigal Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026 - Quiver Quantitative
Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2025 Financial Results and Host Webcast on February 19, 2026 - The Manila Times
Madrigal Pharmaceuticals to Release Fourth-Quarter and - GlobeNewswire
Madrigal Pharmaceuticals (MDGL) Price Target Increased by 10.39% to 562.78 - MSN
Pharma News: How does INNV perform in inflationary periods2025 Trading Recap & Weekly Stock Performance Updates - baoquankhu1.vn
Valuation Update: Will Madrigal Pharmaceuticals Inc outperform during market rallies2025 Performance Recap & Fast Moving Market Watchlists - baoquankhu1.vn
Breakouts Watch: What are analysts price targets for Madrigal Pharmaceuticals IncCEO Change & Technical Entry and Exit Alerts - baoquankhu1.vn
Bull Bear: Is Madrigal Pharmaceuticals Inc stock a value trapIndex Update & Precise Swing Trade Entry Alerts - baoquankhu1.vn
New York State Common Retirement Fund Grows Position in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Gains Expanded Patent Control Over Rezdiffra With Roche - TipRanks
1.12%
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):